Background: Type II diabetes mellitus is associated with multiple metabolic derangements which can cause secondary pathophysiological changes in multiple organ systems. This in turn can impose a heavy burden of morbidity and mortality from micro‑？and macro‑vascular complications. This study aimed to describe the metabolic and therapeutic profile of a subgroup of type 2 diabetic patients who have treatment failure with oral anti-hyperglycemic agents with persistent hyperglycemia despite insulin treatment. Methods: 60 type 2 diabetic patients in treatment failure with oral antidiabetics and under insulin treatment, aged 35 to 70 years, were recruited at the Diabetes Clinic of the University Teaching Hospital of Treichville in Abidjan, Côte d’Ivoire. Blood samples were collected in tubes containing Ethylenediaminetetraacetic Acid (EDTA) to determine glycated hemoglobin (HbA1c). Results: The average age of the population was 54 ± 9.38 years with a sex ratio (M/F) of 0.3, an average BMI of 30.25 ± 5 kg/m2, and an average HbA1c of 10.1% ± 1.6% for an average diabetes duration of 11.8 ± 5.8 years. The average insulin dose was 74.556 ± 16.21 UI/day, and the average duration of insulin treatment was 5.4 ± 3.1 years. The average HbA1c value was 10.1% ± 1.87% in men against 10.03% ± 1.53% in women with no significant difference (p = 0.1). The mean HbA1c values according to patient weight were 10.08% ± 2.05% for normal weight, 9.55% ± 2.26% for overweight, and 10.57% for obese, with no significant difference between the three groups of patients (p = 0.1). Conclusion: This study showed a persistence increase in glycated hemoglobin regardless of the treatment regimen, duration, and dose of insulin treatment in the subpopulation of type 2 diabetic patients.
References
[1]
Naylor, N.R., Greeley, W.A.S., Bell, G. and Philipson H.L. (2011) Genetics and Pathophysiology of Neonatal Diabetes Mellitus. Journal of Diabetes Investigation, 2, 158-169. https://doi.org/10.1111/j.2040-1124.2011.00106.x
[2]
(2021) IDF Diabetes Atlas-10th Edition.
[3]
Adoueni, K.V. (2019) Santé: Le taux de prévalence Nationale du diabète est passé à 6, 2 % selon une enquête coordonnée en 2017. Programme National de Lutte contre les Maladies Métaboliques et de Prévention des Maladies Non Transmissibles (PNLMM/PMNT). https://news.abidjan.net/h/654442.html
[4]
Saraco, M., Hill, M.I., Petersen, M.P., Robinson, S. and Moritsugu, K.P. (2021) Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44, S73-S84. https://doi.org/10.2337/dc21-S006
[5]
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R.B., Mansour, A.D., Almgren, P., Wessman, Y., Shaat, N., Spégel, P., Mulder, H., Lindholm, E., Olle Melande, O., Hansson, Malmqvist, U., Lernmark, A., Lahti, K., Forsén, T., Tuomi, T., Rosengren, A.H. and Groop, L. (2018) Novel Subgroups of Adult-Onset Diabetes and Their Association with Outcomes: A Data-Driven Cluster Analysis of Six Variables. The Lancet Diabetes & Endocrinology, 6, 361-369. https://doi.org/10.1016/S2213-8587(18)30051-2
[6]
Sladek, R. (2018) The Many Faces of Diabetes: Addressing Heterogeneity of a Complex Disease. The Lancet Diabetes & Endocrinology, 6, 348-349. https://doi.org/10.1016/S2213-8587(18)30070-6
[7]
Zander, R., Lang, W. and Wolf, H. (1984) Alkaline Haematin D-575, a New Tool for the Determination of Haemoglobin as an Alternative to the Cyanhaemiglobin Method. I. Description of the Method. Clinica Chimica Acta, 136, 83-93. https://doi.org/10.1016/0009-8981(84)90250-X
[8]
Yapo, A., Assayi, M., Aka, N., Bonetto, R., Comoe, L., Lonsdorfer, A., Monnet, D. and Diaine, C. (1990) Les valeurs de référence de 21 constituants biochimiques sanguins de l’ivoirien adulte présumé sain. Publications Médicales Africaines, 110, 49-57.
[9]
Aouiche, S. and Boudib, A. (2012) L’insulinothérapie utilisée en pratique ambulatoire (à propos de 631 malades). Diabetes & Metabolism, 38, A95.
[10]
Affangla, D.A., Pene, S., Ba, D.M., Dione, J.M., Wabo, A., Ka, M., Leye, M., Diop, Sarr, M. and Touré, K. (2019) Profil du risque cardiovasculaire du diabétique de type 2 suivi en ambulatoire à l’Hôpital Saint Jean de Dieu’, de Thiès. Revue Africaine de Médecine Interne, 6, 21-26.
[11]
LaSalle, J.R. and Berria, R. (2013) Insulin Therapy in Type 2 Diabetes Mellitus: A Practical Approach for Primary Care Physicians and Other Health Care Professionals. Journal of Osteopathic Medicine, 113, 152-162.
[12]
Home, P.D, Dain, M.P., Freemantle, N., Kawamori, R., Pfohl, M., Brette, S., Pilorget, V., Scherbaum, W.A., Vespasiani, G., Vincent, M. and Balkau, B. (2015) Four-Year Evolution of Insulin Regimens, Glycaemic Control, Hypoglycaemia and Body Weight after Starting Insulin Therapy in Type 2 Diabetes across Three Continents. Diabetes Research and Clinical Practice, 108, 350-359. https://doi.org/10.1016/j.diabres.2015.01.030
[13]
Grira, W., Ksira, I., Ounaissa, K., Sfar, H., Ben Brahim, A., Jammoussi, H. and Abid, A. (2016) CA-123: L’insulinothérapie chez le diabétique type 2: En ambulatoire ou en hospitalisation? Diabetes & Metabolism, 42, A68. https://doi.org/10.1016/S1262-3636(16)30255-5
[14]
American Diabetes Association (2023) Standard of Care in Diabetes. Diabetes Care, 46, S99.
[15]
Lotfi, Z., Aboussaleh, Y., Sbaibi, R., Achouri, I. and Benguedour, R. (2017) The Overweight, the Obesity and the Glycemic Control among Diabetics of the Provincial Reference Center of Diabetes (CRD), Kenitra, Morocco. Pan African Médical Journal, 27, 189. (In French)
[16]
Mimita, W., Sebai, I., Ounaissa, K., Abdessalem, H., Ben Brahim, A. and Amrouche, C. (2018) Influence de l’obésité sur l’équilibre glycémique des diabétiques de type 2. Annales d’Endocrinologie, 79, 513. https://doi.org/10.1016/j.ando.2018.06.1058
[17]
Faraoun, K., Fezaz, I., Daoud, M. and Mohammedi, F. (2016) équilibre glycémique en fonction de la durée d’évolution du diabète de type 2 et du traitement: Enquête auprès de 148 patients. Annales d’Endocrinologie, 77, 503. https://doi.org/10.1016/j.ando.2016.07.760
[18]
Virally, M., Laloi-Michelin, M., Coupaye, M., Kevorkian, J.P. and Guillausseau, P.J. (2016) Diabète de type 2 et insulinothérapie: Situations transitoires et définitives. Sang Thrombose Vaisseaux, 17, 525-532.
